Trusted Resources: Education

Scientific literature and patient education texts

111 resources available:
Nonrandomized studies are usually excluded from systematic reviews. This could lead to loss of a considerable amount of information on rare diseases. In this article, we explore the impact of excluding nonrandomized studies on the generalizability of meta-analyses results on mucopolysaccharidosis (MPS) disease. A comprehensive search of systematic reviews on MPS patients up to May 2020 was carried out (CRD42020191217). The primary endpoint was...

Plasma Proteomic Analysis in Morquio A Disease

International journal of molecular sciences Year: 2021
Mucopolysaccharidosis type IVA (MPS IVA) is a lysosomal disease caused by mutations in the gene encoding the enzyme-acetylgalactosamine-6-sulfate sulfatase (GALNS), and is characterized by systemic skeletal dysplasia due to excessive storage of keratan sulfate (KS) and chondroitin-6-sulfate in chondrocytes. Although improvements in the activity of daily living and endurance tests have been achieved with enzyme replacement therapy (ERT) with re...

Mucopolysaccharidosis type II (MPS II) is an X-linked multisystem disorder caused by mutations in the gene encoding iduronate 2-sulfatase (IDS). The clinical manifestations of MPS II include skeletal deformities, airway obstruction, cardiomyopathy, and neurologic deterioration. MPS II has high genetic heterogeneity disorder, and ~ 658 variants of IDS have been reported.

Mucopolysaccharidosis type I (MPS-I) is a rare lysosomal storage disorder caused by deficiency of the enzyme alpha-L-iduronidase, which removes iduronic acid in both chondroitin/dermatan sulfate (CS/DS) and heparan sulfate (HS) and thereby contributes to the catabolism of glycosaminoglycans (GAGs). To ameliorate this genetic defect, the patients are currently treated by enzyme replacement and bone marrow transplantation, which have a number of...

Open-Label Phase 1/2 Study of Vestronidase Alfa for Mucopolysaccharidosis VII

Molecular genetics and metabolism reports Year: 2021
Vestronidase alfa is an enzyme replacement therapy for mucopolysaccharidosis VII (MPS VII). In this open-label, phase 1/2 study, three subjects with MPS VII received intravenous vestronidase alfa administered every other week (QOW) for 14 weeks (2 mg/kg), followed by 24-week forced-dose titration (1, 4, and 2 mg/kg QOW; 8 weeks each), 36-week continuation (2 mg/kg), and long-term extension (4 mg/kg). Vestronidase alfa was well tolerated...
Show more
25 resources available:
MPS VII, also called Sly syndrome, is a rare, life-threatening lysosomal storage disorder, caused by mutations of the GUSB gene, which results in a  deficiency of the β-glucuronidase enzyme. β-glucuronidase plays a key role in the breakdown of glycosaminoglycans (GAGs), previously called mucopolysaccharides. The inability to properly  break do...
Mucopolysaccharidosis VI (MPS VI) is a very rare genetic disorder characterized by a large head, distinctive “coarse” features, and a large tongue. It is also known as Maroteaux-Lamy syndrome, named after two French physicians, Dr. Pierre Maroteaux and his mentor, Dr. Maurice Emil Joseph Lamy, who first described the condition in 1963. Other names for MPS VI include polydystrophic dwarfism and arylsulfatase B deficiency.<...

A Guide to Understanding MPS IV (Morquio Syndrome)

National MPS Society Year: 2021
Mucopolysaccharidosis IV (MPS IV) is a rare genetic disorder characterized by short stature and severe bone disease. It is also known as Morquio syndrome, named after Dr. Morquio, a pediatrician in Montevideo, Uruguay. In 1929, Dr. Morquio described a family of four children affected by this condition. The same year, Dr. Brailsford from Birmingham, England, also described the same characteristics. Consequently, it is sometime...
Stem cell transplantation can be an overwhelming prospect, especially for a family already facing the usually fresh diagnosis of MPS or related disease. Typically, the time line is short, and the amount of information that needs to be assimilated is daunting. A framework of questions for understanding transplant is presented here. The intent is to provide a list of questions you can bring to your health care provider, to help...
What Is MPS I? Mucopolysaccharidosis I (MPS I) is a rare genetic disorder that affects the entire body. It is also known as Hurler syndrome, named after Dr. Gertrude Hurler, a general practitioner, who in 1919 first described a boy and girl with severe symptoms of the condition. In 1962, Dr. Harold Scheie, an ophthalmologist, described individuals who displayed attenuated (less severe...
Talking About the Diagnosis It can be hard to explain the disease to others. You could say that your child has a long-term condition that, depending on the individual’s needs, may require regular healthcare management. You may wish to tell only a few people who need to know, such as family, close friends and key people at school. When talking to your children about Hunter syndrome,...
Show more
10 resources available:
Morquio disease or mucopolysaccharidosis type IVA (Online Mendelian Inheritance in Man No. 253000) is a rare autosomal recessive disease classified in the group of metabolism inborn errors. The glycosaminoglycans accumulate in chondrocytes, which disturbs bone growth and leads to skeletal manifestations, such as skeletal dysplasia and a short stature. In addition, the disproportionate growth of the trachea can lead to airway insufficiency....

Genome Editing in Mucopolysaccharidoses and Mucolipidoses

Progress in Molecular Biology and Translational Science Year: 2021
Mucopolysaccharidoses (MPS) and mucolipidoses (ML) are disorders that alter lysosome function. While MPS are caused by mutation in enzymes that degrade glycosaminoglycans, the ML are disorders characterized by reduced function in the phosphotransferase enzyme. Multiple clinical features are associated with these diseases and the exact mechanisms that could explain such different clinical manifestations in patients are still unknown. Furthermor...
Mucopolysaccharidoses (MPS) are lysosomal storage diseases (LSDs) caused by the deficiency of enzymes essential for the metabolism of extracellular matrix components called glycosaminoglycans (GAGs). To understand the physiopathology and alterations due to the lysosomal accumulation resulting from enzymatic deficiencies and their secondary outcomes can improve the diagnosis and treatment of rare genetic diseases. This work presents a database...
Enzyme replacement therapy (ERT) is available for several lysosomal storage disorders to address the underlying lysosomal enzyme deficiencies that lead to the accumulation of undegraded substrates in multiple organ systems. A typical ERT regimen is a 2–6 h weekly intravenous infusion. ERT administered in a home setting has been reported by patients and caregivers to be both less stressful and more convenient than hospital o...

Musculoskeletal findings in MPS can progress after enzyme replacement. Our aim was to examine synovial recesses, tendons, retinacula and pulleys using ultrasonography for structural and inflammatory changes.

A 10-y-old ‘short-statured’ male presented to us with decreased vision in both the eyes since birth. Ocular examination revealed cloudy corneas in both the eyes (Fig. 1a, b). Family history was unremarkable. Suspecting it to be mucopolysaccharidosis, the child was referred to a pediatrician. Systemic examination revealed global developmental delay, short stature, abdominal distension, umbilical hernia, and hepatosplenomeg...
Show more
30 resources available:
The COVID-19 pandemic has impacted the education of children around the world, forcing a large proportion of teaching to be carried out remotely. The implications of this disruption have yet to be fully elucidated, but initial assessments suggest that COVID-19-related school closures and reliance on virtual learning may have a long-term negative impact on educational attainment and future earnings as well as life expectancy of children in the...

Awake Airway Endoscopy in Mucopolysaccharidosis: A Case Report

Brazilian Journal of Anesthesiology (Elsevier) Year: 2021
Mucopolysaccharidosis (MPS) are a group of rare genetic inherited diseases with a progressive course due to the accumulation of glycosaminoglycans resulting in anatomic abnormalities and organ dysfunction, including the respiratory, cardiovascular, skeletal, and neurological systems that can increase the risk of anesthesia complications. Clinical manifestations are variable, multisystemic, and include severe morphological changes. The anesthet...

Mucopolysaccharidoses Type I Gene Therapy

Journal of inherited metabolic disease Year: 2021
Mucopolysaccharidoses type I (MPS I) is an inherited metabolic disease characterized by a malfunction of the α-l-iduronidase (IDUA) enzyme leading to the storage of glycosaminoglycans in the lysosomes. This disease has longtime been studied as a therapeutic target for those studying gene therapy and many studies have been done using various vectors to deliver the IDUA gene for corrective treatment. Many vectors have difficulties with efficacy...
Mucopolysaccharidosis (MPS) type I is a rare lysosomal storage disorder caused by an accumulation of glycosaminoglycans (GAGs) resulting in multisystem disease. Neurological morbidity includes hydrocephalus, spinal cord compression, and cognitive decline. While many neurological symptoms have been described, stroke is not a widely-recognized manifestation of MPS I. Accordingly, patients with MPS I are not routinely evaluated for stroke, and th...
Hunter syndrome is a rare disease leading to glycosaminoglycan accumulation in tissues. Multiple organs are involved, but prognosis is mainly conditioned by cardiac and respiratory failures. Cardiac valvular impairment is quite common but aortic root dilatation is rarely described. This article covers a case of surgical root replacement due to aortic valve insufficiency and aortic root dilatation documented with magnetic resonance and computed...

Mucopolysaccharidosis type II (MPS II) is a lysosomal disease caused by deficiency of the enzyme iduronate-2-sulfatase (IDS), linked to the X chromosome, producing a wide spectrum of clinical manifestations.

Show more